Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q21099000> ?p ?o }
Showing triples 1 to 61 of
61
with 100 triples per page.
- Q21099000 subject Q7335338.
- Q21099000 subject Q7579524.
- Q21099000 subject Q8493060.
- Q21099000 subject Q8808733.
- Q21099000 subject Q8878420.
- Q21099000 subject Q8971959.
- Q21099000 subject Q9052323.
- Q21099000 abstract "Relugolix (INN) (developmental code name TAK-385) is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (IC50 = 0.12 nM) that is under development for clinical use by Takeda. It is currently in phase II clinical trials for the treatment of endometriosis, uterine leiomyoma, and prostate cancer.A single oral administration of relugolix at a dose of 3 mg/kg has been found to suppress luteinizing hormone levels for more than 24 hours in castrated cynomolgus monkeys, indicating a long duration of action. The drug (80–160 mg/day) has been found to reduce testosterone levels to sustained castrate levels in men with once-daily chronic administration. Lower dosages (10–40 mg/day) are being studied in the treatment of endometriosis and uterine leiomyoma to achieve partial sex hormone suppression. The reasoning behind partial suppression for these conditions is to reduce the incidence and severity of menopausal symptoms such as hot flushes and to avoid bone mineral density changes caused by estrogen deficiency that can eventually lead to osteoporosis.".
- Q21099000 atcPrefix "H01".
- Q21099000 atcSuffix "CC02".
- Q21099000 casNumber "737789-87-6".
- Q21099000 iupacName "1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea".
- Q21099000 pubchem "10348973".
- Q21099000 thumbnail Relugolix_structure.png?width=300.
- Q21099000 wikiPageExternalLink 800028257.
- Q21099000 wikiPageWikiLink Q1318776.
- Q21099000 wikiPageWikiLink Q165328.
- Q21099000 wikiPageWikiLink Q177708.
- Q21099000 wikiPageWikiLink Q181257.
- Q21099000 wikiPageWikiLink Q1858291.
- Q21099000 wikiPageWikiLink Q1981031.
- Q21099000 wikiPageWikiLink Q1988322.
- Q21099000 wikiPageWikiLink Q205764.
- Q21099000 wikiPageWikiLink Q208360.
- Q21099000 wikiPageWikiLink Q21098999.
- Q21099000 wikiPageWikiLink Q21099001.
- Q21099000 wikiPageWikiLink Q2304401.
- Q21099000 wikiPageWikiLink Q277954.
- Q21099000 wikiPageWikiLink Q286779.
- Q21099000 wikiPageWikiLink Q301676.
- Q21099000 wikiPageWikiLink Q30612.
- Q21099000 wikiPageWikiLink Q3931280.
- Q21099000 wikiPageWikiLink Q410943.
- Q21099000 wikiPageWikiLink Q422812.
- Q21099000 wikiPageWikiLink Q461809.
- Q21099000 wikiPageWikiLink Q556281.
- Q21099000 wikiPageWikiLink Q58929.
- Q21099000 wikiPageWikiLink Q7180990.
- Q21099000 wikiPageWikiLink Q725307.
- Q21099000 wikiPageWikiLink Q7335338.
- Q21099000 wikiPageWikiLink Q7579524.
- Q21099000 wikiPageWikiLink Q824258.
- Q21099000 wikiPageWikiLink Q8493060.
- Q21099000 wikiPageWikiLink Q8808733.
- Q21099000 wikiPageWikiLink Q8878420.
- Q21099000 wikiPageWikiLink Q8971959.
- Q21099000 wikiPageWikiLink Q9052323.
- Q21099000 wikiPageWikiLink Q9635.
- Q21099000 atcPrefix "H01".
- Q21099000 atcSuffix "CC02".
- Q21099000 casNumber "737789".
- Q21099000 iupacName "1".
- Q21099000 pubchem "10348973".
- Q21099000 type ChemicalSubstance.
- Q21099000 type Drug.
- Q21099000 type ChemicalObject.
- Q21099000 type Thing.
- Q21099000 type Q8386.
- Q21099000 comment "Relugolix (INN) (developmental code name TAK-385) is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (IC50 = 0.12 nM) that is under development for clinical use by Takeda.".
- Q21099000 label "Relugolix".
- Q21099000 depiction Relugolix_structure.png.